INVISION Partners with TCM Biotech International Corp to Seize NGS Healthcare Coverage Opportunities

Publicly listed TCM Biotech International Corp has announced a strategic partnership with INVISION to address unmet needs in next-generation sequencing (NGS) lab testing. By combining strengths, they will help hospitals establish certified Laboratory Developed Tests (LDTs) and integrate NGS precision medicine solutions. This partnership aims to transform in-house genetic testing, making it more affordable and efficient, benefiting both patients and hospitals.

TCM's General Manager, Wang Ya-Jun, highlighted that in-hospital NGS capabilities will reduce outsourcing, lower costs, and enhance diagnostic accuracy, ultimately driving a new era of precision medicine in Taiwan. Their collaboration leverages INVISION' advanced iNA platform and TCM’s extensive hospital network, targeting over 480 hospitals nationwide.

This initiative is expected to benefit over 20,000 cancer patients annually under Taiwan’s healthcare system, significantly expanding the precision medicine market and setting the stage for future growth in personalized healthcare.